Evidence map›Paper›PMID 36964431›Full record

ArticleEuropean journal of epidemiology2023

Identification of plasma metabolites associated with modifiable risk factors and endophenotypes reflecting Alzheimer's disease pathology.

Ruocheng Dong, Diandra N Denier-Fields, Carol A Van Hulle, Gwendlyn Kollmorgen, Ivonne Suridjan, Norbert Wild, Qiongshi Lu, Rozalyn M Anderson, Henrik Zetterberg, Kaj Blennow and 3 more

Open access · greenAbstract read
In one paragraph

Article in European journal of epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 5 countries.

Ruocheng DongDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA.
Diandra N Denier-FieldsDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA.
Carol A Van HulleDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Gwendlyn KollmorgenRoche Diagnostics International Ltd, CH-6346, Rotkreuz, Switzerland.
Ivonne SuridjanRoche Diagnostics GmbH, 82377, Penzberg, Germany.
Norbert WildRoche Diagnostics GmbH, 82377, Penzberg, Germany.
Qiongshi LuDepartment of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Rozalyn M AndersonDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, S-43180, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, S-43180, Mölndal, Sweden.
Cynthia M CarlssonDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Sterling C JohnsonDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA.
Corinne D EngelmanDepartment of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA. cengelman@wisc.edu.ORCID http://orcid.org/0000-0003-4750-5607
University of Wisconsin–Madison · USRoche Pharma AG (Germany) · DESahlgrenska University Hospital · SERoche (Switzerland) · CH

Funding

Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
Statistical Data Enclave CoreP30AG017266 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Michal Engelman · 1999 to 2026
$17.0M
Center for Demography and EcologyR24HD047873 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI RAYMO, JAMES M · 2004 to 2013
$7.2M
Scientific and Technical CoreP2CHD047873 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Katherine J. Curtis · 2014 to 2026
$5.1M
Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's DiseaseRF1AG054047 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ENGELMAN, CORINNE D. · 2022 to 2025
$3.8M
Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's DiseaseR01AG054047 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ENGELMAN, CORINNE D. · 2016 to 2020
$3.6M
Metabolism of Alzheimer’s Disease: systems and cellular networksR01AG067330 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI ANDERSON, ROZALYN M. · 2020 to 2024
$3.4M
Identifying Metabolomic Risk Factors in Plasma and Cerebrospinal Fluid for Alzheimer's DiseaseR21AG067092 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LU, QIONGSHI · 2020 to 2020
$375k
NCATS NIH HHS UL1 TR000427NIA NIH HHS P30 AG017266NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG054047NIA NIH HHS R01 AG067330NIA NIH HHS R21 AG067092NIA NIH HHS RF1 AG054047NICHD NIH HHS P2C HD047873NICHD NIH HHS R24 HD047873
6 · The paper itself

Abstract

Modifiable factors can influence the risk for Alzheimer's disease (AD) and serve as targets for intervention; however, the biological mechanisms linking these factors to AD are unknown. This study aims to identify plasma metabolites associated with modifiable factors for AD, including MIND diet, physical activity, smoking, and caffeine intake, and test their association with AD endophenotypes to identify their potential roles in pathophysiological mechanisms. The association between each of the 757 plasma metabolites and four modifiable factors was tested in the wisconsin registry for Alzheimer's prevention cohort of initially cognitively unimpaired, asymptomatic middle-aged adults. After Bonferroni correction, the significant plasma metabolites were tested for association with each of the AD endophenotypes, including twelve cerebrospinal fluid (CSF) biomarkers, reflecting key pathophysiologies for AD, and four cognitive composite scores. Finally, causal mediation analyses were conducted to evaluate possible mediation effects. Analyses were performed using linear mixed-effects regression. A total of 27, 3, 23, and 24 metabolites were associated with MIND diet, physical activity, smoking, and caffeine intake, respectively. Potential mediation effects include beta-cryptoxanthin in the association between MIND diet and preclinical Alzheimer cognitive composite score, hippurate between MIND diet and immediate learning, glutamate between physical activity and CSF neurofilament light, and beta-cryptoxanthin between smoking and immediate learning. Our study identified several plasma metabolites that are associated with modifiable factors. These metabolites can be employed as biomarkers for tracking these factors, and they provide a potential biological pathway of how modifiable factors influence the human body and AD risk.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesEndophenotypesAdultBeta-CryptoxanthinBiomarkersCaffeineHumansMiddle AgedRisk Factorstau ProteinsAmyloid beta-PeptidesBeta-CryptoxanthinBiomarkersCaffeinetau ProteinsAlzheimer’s biomarkersCaffeineCognitionMediationMIND dietPhysical activityPlasma metabolitesSmoking

Identifiers

PMID36964431
PMCPMC11070200
OpenAlexW4360941975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.